Talent Managers Declare Gig Work the 'New Normal' According to Research from Kelly Services®
Research Also Shows Differences between Gig Laggards and Innovators
TROY, Mich., March 26, 2018 (GLOBE NEWSWIRE) -- New research from Kelly Services ® provides insight into why companies hire gig workers and what the most innovative among them do differently from their peers. Surveying 2,100 talent managers worldwide-across industries and career disciplines-global workforce solutions provider, Kelly Services, uncovered new insights about gig adoption rates, the outlook for gig hiring, the growing influence of independents, and areas for competitive innovation. The most noteworthy survey findings include:
- Gig work becoming the new normal: 65% of talent/hiring managers say the gig economy is rapidly becoming the new normal for how businesses organize work.
- A flexible workforce is the way forward: Nearly 3 in 4 talent/hiring managers (73%) say a much more flexible and fluid workforce will emerge as a way to navigate an increasingly dynamic global business climate.
- Workers are free agents* by choice : 75% of global free agents choose gig work for positive reasons, seeing it as a way to improve their personal and professional lives.
- The advantages are clear: 43% of organizations engaging gig workers experience at least a 20% labor cost savings and 72% say using gig workers/free agent talent gives their team/organization a competitive advantage.
"The research shows that hiring gig workers is pervasive across regions and industries, but there's still room for improvement," says Amy Anger, vice president and global practice strategy lead, Gig Economy, for Kelly Services. "The majority of hiring managers say a flexible workforce will be a key way to differentiate and compete in the future, yet 39% of organizations are what we call gig-work laggards: they aren't currently using gig workers heavily nor strategically."
What factors are driving the gig economy?
- Skills Gap: Companies today need a ready supply of knowledge workers in emerging areas of expertise to stay competitive.
- Work/life design: More and more freelancers are opting for gig work by choice rather than economic necessity. As independents, they have greater autonomy about how, when and where to work-and employers are feeling pressure to adapt to these preferences. The research shows seven out of 10 talent managers using free agents see the employer-worker relationship shifting, with talent asserting more leverage.
- Technology advancements: The surge in the "human cloud" (technologies that enable virtual collaboration) have made gig work much more cost-effective and productive. Technological improvements, generally, have enabled more people to work from anywhere - creating a cycle of increasing demand to have more flexibility in their work style.
- Economic pressure: Volatile market conditions have made many employers wary of adding to their permanent payrolls and more receptive to the concept of a scalable, variable workforce in order to be competitive.
"The research findings are fascinating not just for global organizations seeking an edge over competitors, but for the entire gig economy ecosystem-from the growth of cloud-based technology solutions that power the independent workforce, to the growing interest among those seeking independent work to become 'digital nomads,' or professionals who work whenever and wherever they want, not tied to an office or even a city," says Anger.
Why do companies seek out gig labor? Most cite cost savings and filling talent gaps, but a large number point to knowledge transfer as a key benefit.
60% use gig labor to bridge a talent or capacity gap and 57% use it to realize cost savings and/or efficiencies. The research also shows that a significant portion of hiring managers see independent workers as a critical source of outside knowledge and experience; 49% use gig workers to infuse talent into their organizations and grow internal expertise.
"For some forward-thinking organizations, hiring independent workers is a way to import new and innovative ideas," explains Anger. "Independents tend to work across a higher number of organizations and industries. By soaking up knowledge and experience from multiple engagements, they can be tremendously valuable as innovative problem solvers. Our research shows that 75% of those who engage gig economy workers believe that free agency helps individuals build a skill repertoire through various gigs-skills they can infuse into the organizations that engage them."
To understand the full potential of the gig workforce, watch the innovators
The Kelly Services research includes a Workforce Optimization Maturity Index which provides insight into the maturity level with which firms currently leverage the gig workforce. Those that use gig workers less effectively than their peers are called laggards; those with stronger skills and commensurate benefits are competents and differentiators. The most-skilled organizations are innovators.
Innovators make up just 13% of all companies, but they can reap big rewards when it comes to deploying and leveraging gig labor. Innovators are heavy users of gig labor and tend to use independents for highly visible and strategic challenges. They view gig workers not as outsiders, but as a critical and valuable component of the overall workforce. And innovators are highly advanced in how they use technology to aid in the practices and processes of managing gig labor. (Not surprisingly, this group also reports the highest level of cost savings: innovators are nearly 3 times more likely than laggards to save over 30% on labor cost).
Survey Methodology: The 2017 Gig Economy Talent Manager Research was conducted online by Inavero on behalf of Kelly Services. The study surveyed over 2,100 talent managers from around the globe.
For additional information, please click here.
About Kelly Services
As a global leader in providing workforce solutions, Kelly Services, Inc. (Nasdaq:KELYA) (Nasdaq:KELYB) and its subsidiaries, offer a comprehensive array of outsourcing and consulting services as well as world-class staffing on a temporary, temporary-to-hire, and direct-hire basis. Kelly® directly employs nearly 500,000 people around the world in addition to having a role in connecting thousands more with work through its global network of talent suppliers and partners. Revenue in 2017 was $5.4 billion. Visit kellyservices.com and connect with us on Facebook, LinkedIn, and Twitter.
* Today there are 50 million free agents in the U.S., comprising 33% of the U.S. workforce. Globally, free agents/gig workers make up 31% of the workforce. Gig work describes any engagement for which talent is paid for a discrete task, project or period of time. Dozens of terms fall under the "gig work" umbrella-from freelancers and independent consultants, to micropreneurs and independent contractors. All of these are referred to as part of the gig economy or on-demand economy.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Kelly Services, Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
4D Announces Positive Data From Phase 1b Study of Thetanix in Paediatric Crohn's Diseases Patients and Publication of Studies Showing Strong Efficacy of Thetanix in Preclinical Models of IBD24.9.2018 08:00 | Pressemelding
LEEDS, United Kingdom, Sept. 24, 2018 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announces positive top-line results for its Phase 1b study of Thetanix in paediatric patients with Crohn’s disease. The study achieved its primary objective, demonstrating that Thetanix was well tolerated with a good safety profile. The randomised, double-blind, placebo-controlled study was conducted in two parts, with a single-dose phase and a multiple-dose phase and treated a total of 18 subjects aged 16-18 with Crohn’s disease. In the single-dose phase, eight subjects were given a single dose of either Thetanix or placebo. In the multiple-dose phase, 10 subjects were given either Thetanix or placebo twice daily for seven consecutive days. The Company also announces the publication of data demonstrating the efficacy of Thetanix in pre-clinical models of inflammatory bowel disease (IBD). The data, published in the journal
Researchers, Survivors, Advocates and Physicians Convene to Discuss Innovations in Lung Cancer Research, Treatment and Advocacy at the Largest-Attended World Conference on Lung Cancer24.9.2018 01:00 | Pressemelding
TORONTO, Sept. 23, 2018 (GLOBE NEWSWIRE) -- Patients, survivors and advocates joined researchers and physicians from across the globe to discuss the future of lung cancer at the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC) in Toronto, Canada. The conference’s first press briefing highlighted the record-breaking number of registered attendees (over 7,300), reviewed patient-caregiver communities working to accelerate research, evaluated survey data on the emotional needs of lung cancer survivors and underscored the impact of comprehensive genomic profiling on patient care. The press conference opened with a welcome message from conference co-presidents Natasha B. Leighl, M.D., BSc, MSc; Andrea Bezjak, M.D., FRCPC, MSc; and Gail Darling M.D., FRCSC, who have worked tirelessly to make this year’s conference in Toronto highly successful. Oncogene-driven patient-caregiver communities creating new paradigm for non-small cell lu
Bombardier Delivers First 90-seat Q400 Aircraft to SpiceJet21.9.2018 16:00 | Pressemelding
SpiceJet becomes the first airline to take advantage of the Q400 aircraft’s increased profit potential TORONTO, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft today announced the delivery of its first 90-seat Q400 aircraft. The aircraft was handed over to India’s SpiceJet Limited (“SpiceJet”) the launch operator for the extra-capacity, 90-seat aircraft. “We are excited to induct the 90-seat Q400 aircraft into our fleet,” said Ajay Singh, Chairman and Managing Director, SpiceJet. “The additional seats and performance improvements will result in substantial reduction in unit costs and also we will enable us to address our market needs in the regional space.” “The delivery of the first 90-seat Q400 aircraft showcases the commitment of Bombardier’s Q Series turboprop program to respond to customer requirements as they address traffic growth in regional markets,” said Todd Young, Head of the Q Series Aircraft Program, Bombardier Commercial Aircraft. “I thank and congratul
Service Providers Speed Deployment, Reduce Costs with Patton Cloud Edge Orchestration Service20.9.2018 22:16 | Pressemelding
Now, Telecom and UCaaS service providers can easily provision, manage, monitor, secure, alert, troubleshoot, analyze, and optimize services on the customer premise GAITHERSBURG, Md., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Patton Electronics—US-manufacturer of UC, cloud, and IoT-enabling solutions for carrier, enterprise, and industrial networks—has launched the new Patton Cloud service for carriers and service providers that deliver All-IP and hybrid voice-and-data services to business subscribers. Patton Cloud delivers a low-cost, easy-to-use, web-based edge-orchestration service that delivers a superior user experience. It offers remote touchless provisioning, monitoring, and troubleshooting—as well as security and alerting tools that reduce service turn-up costs, trouble tickets, and subscriber attrition. The Patton Cloud service offers quality-control mechanisms including pro-active monitoring and troubleshooting—combined with feature-license distribution pools for managing value-added
Inspirata Promotes Top Executives to Expanded Roles in Digital Pathology20.9.2018 21:12 | Pressemelding
Inspirata Founder and Executive Vice President, Mark Lloyd, is taking on an expanded role overseeing product management, and Inspirata Senior Vice President, Andrew Chomos, has been appointed to General Manager, Digital Pathology, overseeing the Center of Excellence in Pittsburgh along with all North America sales and customer support efforts. Tampa, FL, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced today that two of its executives have taken on expanded roles in the company. The two are Inspirata Executive Vice President and Founder, Mark Lloyd, and Senior Vice President and General Manager, Digital Pathology, Andrew Chomos. Dr. Lloyd has accepted the expansion of his role to include product management for Digital Pathology. He is former cancer researcher at both Lombardi Cancer and Moffitt Cancer Center and is Inspirata’s foremost subject matter expert and thought leader on digital pathology and image
Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections20.9.2018 19:08 | Pressemelding
– Broad Product Label for Treatment of Complicated Intra-Abdominal Infections – – Phased Commercial Launch Expected in the First Half of 2019 – WATERTOWN, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that the European Commission (EC) has adopted the Decision granting marketing authorisation for XERAVA (eravacycline) for injection for the treatment of complicated intra-abdominal infections (cIAI) in adults in the European Union. In clinical trials, XERAVA was well-tolerated and achieved high clinical cure rates in patients with cIAI, demonstrating statistical non-inferiority to two widely used comparators – ertapenem and meropenem. “The European approval of XERAVA, right after our recently announced FDA approval, marks our second significant regulatory approval within one month
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom